These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 12544978)

  • 21. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.
    Greenman RL; Schein RM; Martin MA; Wenzel RP; MacIntyre NR; Emmanuel G; Chmel H; Kohler RB; McCarthy M; Plouffe J
    JAMA; 1991 Aug; 266(8):1097-102. PubMed ID: 1865542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endotoxin removal by direct hemoperfusion with an adsorbent column using polymyxin B-immobilized fiber ameliorates systemic circulatory disturbance in patients with septic shock.
    Uriu K; Osajima A; Hiroshige K; Watanabe H; Aibara K; Inada Y; Segawa K; Anai H; Takagi I; Ito A; Kamochi M; Kaizu K
    Am J Kidney Dis; 2002 May; 39(5):937-47. PubMed ID: 11979337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statins in prevention and treatment of severe sepsis and septic shock.
    Kouroumichakis I; Papanas N; Proikaki S; Zarogoulidis P; Maltezos E
    Eur J Intern Med; 2011 Apr; 22(2):125-33. PubMed ID: 21402241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New criteria for selecting the proper antimicrobial chemotherapy for severe sepsis and septic shock.
    Periti P; Mazzei T
    Int J Antimicrob Agents; 1999 Jul; 12(2):97-105. PubMed ID: 10418753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Analysis of correlation between inflammatory parameters and severity of sepsis caused by bacterial bloodstream infection in septic patients].
    Zhao L; Zang X; Chen W; Sheng B; Gu X; Zhang J
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2015 Jun; 27(6):448-53. PubMed ID: 26049182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of endotoxin response by synthetic TLR4 antagonists.
    Hawkins LD; Christ WJ; Rossignol DP
    Curr Top Med Chem; 2004; 4(11):1147-71. PubMed ID: 15279606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
    Gorelick KJ; Chmel H
    Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monophosphoryl lipid A as a prophylactic for sepsis and septic shock.
    Gustafson GL; Rhodes MJ; Hegel T
    Prog Clin Biol Res; 1995; 392():567-79. PubMed ID: 8524964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent developments in the treatment of sepsis.
    Sharma VK; Dellinger RP
    Expert Opin Investig Drugs; 2003 Feb; 12(2):139-52. PubMed ID: 12556210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging therapies for sepsis and septic shock.
    Oh HM
    Ann Acad Med Singap; 1998 Sep; 27(5):738-43. PubMed ID: 9919353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functionalized dendrimers as endotoxin sponges.
    Cromer JR; Wood SJ; Miller KA; Nguyen T; David SA
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1295-8. PubMed ID: 15713373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Macrophage migration inhibitory factor (MIF) modulates innate immune responses induced by endotoxin and Gram-negative bacteria.
    Roger T; Glauser MP; Calandra T
    J Endotoxin Res; 2001; 7(6):456-60. PubMed ID: 11753217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction of antimicrobial peptide temporin L with lipopolysaccharide in vitro and in experimental rat models of septic shock caused by gram-negative bacteria.
    Giacometti A; Cirioni O; Ghiselli R; Mocchegiani F; Orlando F; Silvestri C; Bozzi A; Di Giulio A; Luzi C; Mangoni ML; Barra D; Saba V; Scalise G; Rinaldi AC
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2478-86. PubMed ID: 16801429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibiotic-induced release of bacterial cell wall components in the pathogenesis of sepsis and septic shock: a review.
    Periti P; Mazzei T
    J Chemother; 1998 Dec; 10(6):427-48. PubMed ID: 9876052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing antimicrobial therapy of sepsis and septic shock: focus on antibiotic combination therapy.
    Vazquez-Grande G; Kumar A
    Semin Respir Crit Care Med; 2015 Feb; 36(1):154-66. PubMed ID: 25643278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peptide-based treatment of sepsis.
    Brandenburg K; Andrä J; Garidel P; Gutsmann T
    Appl Microbiol Biotechnol; 2011 May; 90(3):799-808. PubMed ID: 21369803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale of extracorporeal removal of endotoxin in sepsis: theory, timing and technique.
    Ronco C; Piccinni P; Kellum J
    Contrib Nephrol; 2010; 167():25-34. PubMed ID: 20519896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiendotoxin approaches to septic shock therapy.
    Van Dervort AL; Danner RL
    Crit Care Med; 1994 Apr; 22(4):539-41. PubMed ID: 8143457
    [No Abstract]   [Full Text] [Related]  

  • 39. Recent developments in our understanding of sepsis: evaluation of anti-endotoxin antibodies and biological response modifiers.
    Talan DA
    Ann Emerg Med; 1993 Dec; 22(12):1871-90. PubMed ID: 8239111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endotoxin elimination in sepsis: physiology and therapeutic application.
    Buttenschoen K; Radermacher P; Bracht H
    Langenbecks Arch Surg; 2010 Aug; 395(6):597-605. PubMed ID: 20582603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.